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Summary  
Background: The careHPV assay is a test for high-risk (HR) HPV detection designed to be 
affordable in resource-poor settings. We evaluated the performance of careHPV screening 
among 1052 women living with HIV/AIDS included in the HARP (HPV in Africa Research 
Partnership) study in Burkina Faso (BF) and South-Africa (SA). 
Methods: Cervical samples were tested for HR-HPV by the careHPV and the INNO-LiPA 
HPV genotyping Extra assays. All women had Pap smear testing, visual inspection with acetic 
acid/Lugol’s iodine (VIA/VILI) and colposcopy. Cervical biopsies were obtained for 
participants who were HR-HPV DNA positive by careHPV or who had abnormalities 
detected on cytology, VIA/VILI or colposcopy. 
Results: Overall, 45.1% of women had a positive careHPV test (46.5% in BF, 43.8% in SA). 
The careHPV positivity rate increased with the grade of cytological lesions. Sensitivity and 
specificity of careHPV for the diagnosis of CIN2+ (n=60, both countries combined) were 
93.3% (95%CI: 83.8-98.2) and 57.9% (95%CI: 54.5-61.2), respectively. Specificity increased 
with CD4 count. careHPV had a similar clinical sensitivity but higher specificity than the 
INNO-LiPA assay  for detection of CIN2+.  
Conclusion: Our results suggest that careHPV testing is a reliable tool for cervical cancer 
screening in HIV-1-infected women in sub-Saharan Africa.  
Keywords: careHPV, cervical screening, HIV/AIDS, Africa 
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Introduction 
Cervical cancer, which is the fourth most common cancer in women worldwide (Ferlay et al, 
2015), is the most frequent cancer and the leading cause of cancer death in Sub-Saharan 
African women (Denny & Anorlu, 2012). Infection with human immunodeficiency virus type 
1 (HIV-1) is an additional risk factor for the development of precancerous and cancerous 
cervical lesions (De Vuyst et al, 2008). Therefore, there is a need for developing preventive 
measures in this highly exposed population of African women living with HIV/AIDS 
(WLHA). Unfortunately, cervical cancer screening programs are lacking in most Sub-Saharan 
African countries and the diagnosis of cervical cancer is generally made at an advanced stage 
of the disease when treatment is unavailable or ineffective.  
The development of precancerous cervical lesions that may evolve to invasive carcinoma is 
associated with persistent cervical infection with carcinogenic types of human 
papillomaviruses (HPV) designated as high-risk (HR) HPV. It has been shown that detection 
of HR-HPV in cervical samples is a highly sensitive tool for identifying women at risk of 
precancerous or cancerous cervical lesions (Cuzick et al, 2008; Ronco et al, 2014), but 
evaluation among WLHA have only rarely been conducted. 
The careHPV assay (Qiagen Corporation, Gaithersburg, MD) is a qualitative test for HR-
HPV detection targeting 14 HR-HPV types: HPV16, HPV18, HPV31, HPV33, HPV35, 
HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV 66 and HPV68. This 
microplate assay, based on the hybridization of HR-HPV DNA with a cocktail of RNA probes 
and chemiluminescence signal amplification, was adapted from the Hybrid Capture 2 (HC2) 
assay (Qiagen) and designed to be simpler, more rapid to use, and more affordable than HC2 
in resource-poor settings (Qiao et al, 2008; Gage et al, 2012). 
HARP (HPV in Africa Research Partnership) is a research program conducted among WLHA 
in Burkina Faso and South Africa with the aim to prospectively evaluate several screening 
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approaches for prevention of cervical cancer. In the first round of screening, we have shown 
that, compared with the INNO-LiPA HPV genotyping Extra assay, HC2 performed well in 
this population, with a similar sensitivity and a higher specificity for the diagnosis of high-
grade cervical intraepithelial neoplasia (CIN) grade 2 or more severe (CIN2+). We have 
already reported an excellent agreement between HC2 and careHPV in a subgroup of HARP 
participants (Ngou et al, 2013), comparable to what was found in HIV-seronegative women in 
China (Chen et al, 2014; Lin et al, 2014). However, it remained to be demonstrated that 
careHPV had a good performance among African WLHA. For this reason, we used the 
second round of screening in HARP 18 months after enrolment to evaluate the performance of 
careHPV for the detection of CIN2+.  
 
Materials and Methods 
Study population 
Participants were confirmed HIV-1- seropositive women aged 25-50 years recruited from the 
HIV outpatient clinic of the University Hospital of Ouagadougou, Burkina Faso (BF), and 
HIV treatment centres and surrounding primary health care clinics in Hillbrow, Johannesburg, 
South Africa (SA). Eligible women were invited for inclusion in the study if they were 
resident in the recruitment city, had not had a total hysterectomy or history of cervical cancer 
treatment and were not pregnant or less than 8 weeks post-partum.  
Ethical approval was granted from Ministry of Health in Burkina Faso (no. 2012-12-089), the 
Witwatersrand University in South Africa (no. 110707), and the London School of Hygiene 
and Tropical Medicine (no. 7400). All women provided a written informed consent at the 
screening visit, and they were given a reflection period of at least 7 days before enrolment in 
the study. A second written informed consent was obtained at the enrolment visit for 
enrolment and follow-up over scheduled visits at months (M) 6, 12 and 18. 
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careHPV assay 
At the M18 visit, endo- and ectocervical sampling was performed using the careHPV sample 
collection device consisting of a careBrush and a vial containing 1 ml of careHPV collection 
medium (Qiagen). After collection, the brush was stirred into the collection medium, the cell 
collection was homogeneized by vortexing and divided into four 0.25-ml aliquots. One 
aliquot was maintained at 4°C until careHPV analysis, performed within less than 4 weeks, 
and the others were cryopreserved at -80°C. The careHPV test was performed using 50µl of 
cervical sample in collection medium according to the manufacturer's instruction. The tests 
were performed at the respective sites by medical scientists specifically trained by a Qiagen's 
scientist. The positive or negative result of the careHPV assay was displayed by the careHPV 
test controller without additional specification of the luminescent signal intensity. 
 
HPV detection and genotyping 
All cervical specimens were tested using the INNO-LiPA HPV genotyping Extra® assay 
(Fujirebio, Les Ulis, France) as previously described (Ngou et al, 2015).  This assay, which is 
based on PCR amplification of HPV DNA using broad-spectrum SPF10 consensus primers 
followed by hybridization of the amplicons with type-specific oligonucleotides probes 
immobilized on membrane strips, allows identification of 28 HPV types, including the 14 HR-
HPV types targeted by the careHPV assay, the possible carcinogenic types HPV26, HPV53, 
HPV69, HPV70, HPV73 and HPV82, and the low-risk types HPV6, HPV11, HPV40, HPV43, 
HPV44, HPV54, HPV71 and HPV74. Testing was performed on an aliquot preserved 
at -80°C. A sample was considered HPV-positive if at least one of the type-specific probes or 
one of the HPV control probes were detected.  
 
Cytological and histological analysis 
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 An additional cervical brush was collected from the ecto- and endocervix and rolled on a 
glass slide which was fixed with ethanol for cytological reading using the Papanicolaou 
method (Pap test). Conventional cytology was used as liquid-based cytology was not available 
at that time in the African laboratories involved in the study. All participants had visual 
inspection with acetic acid/Lugol’s iodine (VIA/VILI) performed by trained nurses and 
colposcopy performed by trained colposcopists. Systematic four-quadrant biopsy and directed 
biopsy from any suspicious lesions were performed for participants testing positive by 
careHPV or who had abnormalities detected on cytology (≥ASC-US), VIA/VILI or 
colposcopy.  
The Bethesda system for reporting cervical cytology (Smith, 2002) was used for cytology 
results and the CIN classification for histology results. Cytological and histological slides 
were independently examined at each site by two senior pathologists blinded to the other 
study results. Pathologists were trained before the start of the study in order to harmonize 
slide interpretation between sites. A quality assessment of over 10% of slides was organized 
at 6-month intervals by the reference pathology laboratory at Montpellier University Hospital 
for both sites, in addition to existing internal and external quality assurance schemes adhered 
to by the National Health Laboratory Service (NHLS) in SA. 
The HARP end-point committee composed of 5 pathologists reviewed all histological slides 
from women with a local diagnosis of CIN2+ and approximately 10% of slides from women 
with normal or CIN1 histological findings; the final classification of lesions was based on a 
consensus of the committee. 
 
Data analysis 
Women included in this analysis comprise all of the HARP participants who were not lost to 
follow-up at M18 visit, including women who may have been treated for CIN2+ detected at 
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baseline, except if this had been by hysterectomy. Proportions were compared between groups 
using Chi-square or Fisher’s exact test, as appropriate. Sensitivity, specificity, positive and 
negative predictive values (PPV and NPV) were calculated with exact binomial 95% 
confidence intervals (CI), separately for each country first and then for both countries 
combined (sensitivity and specificity only). Additionally, sensitivity and specificity analysis 
to detect CIN2+ was stratified by levels of CD4 T-cell counts (<200 cells/mm3, 201-350 
cells/mm3, >350 cells/mm3) at entry in the study and at the time of screening (M18), and by 
age (<35y and >35y) and compared across strata using Chi-squared or Fisher’s exact tests as 
appropriate. The comparative analysis of performance of all other methods and triage 
combinations for the detection of CIN2+ is not reported in this paper. Agreement between the 
careHPV assay and the INNO-LiPA HPV genotyping Extra assay was assessed by percentage 
overall agreement and prevalence-adjusted bias-adjusted (PABA) kappa coefficient. All 
analyses were done using the Stata version 14 software (Stata Corp, College Station, TX, 
USA).  
 
Results 
 
A total of 1249 WLHA were enrolled in the study between November 2011 and October 2012, 
625 in BF and 624 in SA. The analysis was based on the 1052 women (94% overall; BF=492; 
SA=560) who had an adequate careHPV result at the M18 visit, which actually occurred at a 
median 16 months [interquartile range (IQR), 15.5-16.8] (Figure 1). Among those with valid 
careHPV result, 929 (88%; BF=426, SA=503) also had valid cytology results, and  976 
returned for colposcopy (93%; BF=469,  SA=507). Adequate biopsies were taken from 718 
(74%) women, 265 (57%) in BF and 453 (89%) in SA. A total of 225 women (BF=179; 
SA=46) did not require biopsy as they had no abnormal cytology, VIA/VILI or colposcopy 
findings and a negative careHPV test; they were classified as having “normal/negative” 
9 
 
histology. Thirty three women (BF=25; SA=8) did not have biopsy taken for reasons such as 
pregnancy, pain, cervix atrophy or stenosis. Overall, valid histology results were available for 
943/1052 (90%) women, 444 (90%) in BF and 499 (89%) in SA. These women had a median 
(IQR) CD4+ T-cell count of 495 (355-684) cells/mm3, 583 (412-813) cells/mm3 in BF and 
438 (331-571) cells/mm3 in SA. The number of women on ART was 796 (75%), 400 (81%) in 
BF and 396 (71%) in SA, including those who were initiated onto treatment during the study 
period. 
Overall, 45.1% (474/1052) of women had a positive careHPV test, 46.5% (229/492) in BF 
and 43.8% (245/560) in SA (P=0.36). Any HPV DNAwas detected in 83.4% (877/1052) 
cervical samples, [80.3% (395/492) in BF and 86.1% (482/560) in SA] by the INNO-LiPA 
genotyping Extra assay. When considering only the 14 HR-HPV types targeted by careHPV, 
70.0% (736/1052) of samples [67.9% (334/492) in BF and 71.8% (402/560) in SA] were 
positive by genotyping. The overall agreement between the two tests for HR-HPV DNA 
detection was 62.4%, with a PABA-Kappa value of 0.25 (95%CI: 0.19-0.31) indicating a fair 
agreement. However, when analysis was restricted to the 60 women with CIN2+, the 
agreement between tests was 93.3% with a PABA-Kappa value of 0.87 (95%CI: 0.74-0.99) 
indicating an excellent agreement. Compared with the INNO-LiPA HPV genotyping Extra 
assay, analytical sensitivity of careHPV for detecting HR-HPV DNA was 55.4% (95%CI: 
51.8%-59.1%). The positivity rates of the careHPV test according to the HR-HPV types 
detected by genotyping in single HR-HPV infection cases are presented in Table 1.  The 
detection rates ranged from 40.0% (HPV56) to 86.4% (HPV58).  
Cytology results showed that the overall prevalence of high-grade squamous intraepithelial 
lesions (HSIL) was 10.5% (98/929) with a prevalence of 2.1% (9/426) in BF and of 17.7% 
(89/503) in SA. As shown in Table 2, the prevalence of HR-HPV detected by careHPV or the 
INNO-LiPA genotyping Extra assay increased with the lesion grade (P<0.0001), and the 
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sensitivity and specificity values, combined for both countries, for the detection of HSIL were 
respectively, 88.8% (87/98) and 61.8% (514/831) for careHPV, and 91.8% (90/98) and 33.7% 
(280/831) for INNO-LIPA genotyping Extra (14 types). The sensitivity of careHPV for 
detecting HSIL was lower in SA than in BF (87.6% vs 100%) but specificity was higher 
(64.7% vs  56.3%). Negative predictive values for HSIL were 100% (95%CI: 98.4-100.0) and 
96.1% (95%CI: 93.1-98.0) in BF and SA, respectively.  
A total of 60 (6.4%) women had high-grade (CIN2+) histological lesions, 9 (2.0%) in BF and 
51 (10.2%) in SA (P<0.0001). Overall, the careHPV test was positive in 56/60 (93.3%) 
women with CIN2+, 9 (100%) in BF and 47 (92.2%) in SA, respectively (P>0.5). The 
performance characteristics of the careHPV and INNO-LiPA genotyping Extra assays for the 
diagnosis of CIN2+ in each country and overall are presented in Table 3. The negative 
predictive values of both tests were very similar (98.6% to 100%), and when combining the 
results for the two countries, the careHPV test was slightly less sensitive (93.3% vs 96.7%) 
but more specific (57.9% vs 32.9%) than the INNO-LiPA HPV genotyping Extra assay. 
Stratification of results by CD4+ T-cell count showed that there was no significant difference 
in sensitivities by CD4+ T-cell count levels at study entry or contemporary to CIN biopsy at 
M18. However, specificities decreased with decreasing CD4+ T-cell counts both at study 
enrolment (P=0.01) and at M18 (P=0.0008), which corresponded to increasing HR-HPV 
prevalences (Table 4). Participants on ART at the time of enrolment had lower HR-HPV 
prevalence at M18. careHPV was slightly more specific in these women (P=0.05). There 
were no significant difference by age (Table 4). 
 
Discussion  
Considering the high prevalence of HIV infection in sub-Saharan Africa and the fact that 
WLHA have an increased risk of development of cervical precancerous and cancerous lesions, 
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it is important to target this population in cervical cancer prevention programs. It is also 
important to verify that the performance of screening tests is not modified by HIV serostatus. 
Several studies conducted in China (Qiao et al, 2008), India (Labani et al, 2014), Thailand 
(Trope et al, 2013), Brazil (Lorenzi et al, 2013), Nigeria (Gage et al, 2012) on clinician- or 
patient-collected cervical samples have shown that cervical screening based on careHPV 
testing was a feasible and performant strategy in low-resource settings. However, none of 
these studies had been conducted among WLHA. Thus, the possible impact of HIV infection 
on the performance of careHPV for cervical screening deserved further investigation.  
As expected, the positivity rate of careHPV increased with the grade of cytological lesions, 
ranging from 87.6% (SA) to 100% (BF) in women with HSIL. The endpoint in this study was 
CIN2+ and our results indicate that careHPV detected CIN2+ with a high sensitivity (93.3%) 
and a high negative predictive value (≥99%) in this population of WLHA. The sensitivity of 
careHPV for detecting CIN2+ observed in the present study was very similar to that (94.3%) 
recently reported in the only other study among WLHA, although specificity was not reported 
in that Ugandan study (Bansil et al, 2015). The overall specificity of careHPV was relatively 
low (58%) and varied by CD4 T cell strata (between 43% and 62%). A similar finding, albeit 
with even lower specificity, was reported in a study of a similar group of WLHA in 
Johannesburg tested with HC2 (Firnharber et al, 2013). The high prevalence of HR-HPV in 
this highly exposed population, which increases by level of immune-suppression, may lead to 
low test specificity, as not all HPV infections will progress to CIN2+ lesions, or only much 
later.  
Comparison of the careHPV test with the INNO-LiPA HPV genotyping Extra assay showed 
that careHPV is less sensitive than the genotyping assay for the detection of HR-HPV DNA, 
and that the rate of detection varies according to the different HR-HPV types. However, 
despite the higher analytical sensitivity of the INNO-LiPA assay for HR-HPV DNA detection, 
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the clinical sensitivity of the two tests for the diagnosis of CIN2+ was very comparable and 
the careHPV test had superior specificity. We may infer that the observed differences in 
analytical sensitivity of careHPV may not affect its usefulness as a screening test. We have 
previously reported that the HC2 assay, from which the careHPV test is derived, had an 
overall sensitivity and specificity of 88.8% and 55.2%, respectively, to detect CIN2+ lesions 
in this study population at their first round of screening (Ngou et al, 2015), which would make 
that HPV assay suitable for screening. The overall sensitivity and specificity of 93.3% and 
57.9% observed in the present study indicate that careHPV would perform equally well for 
cervical cancer screening of WLHA in sub-Saharan Africa. Given the relative low specificity 
of HPV testing, a triage test such as cytology might be required to determine which women 
should be referred to colposcopy. The cost-effectiveness of this approach should be evaluated.  
The high prevalence of HR-HPV infection and CIN2+ observed in this study are in agreement 
with data obtained among similar populations in sub-Saharan Africa (Hawes et al, 2003; 
Didelot-Rousseau et al, 2006; Singh et al, 2009; Firnhaber et al, 2010; De Vuyst et al, 2012). 
Interestingly, whilst HR-HPV prevalence as determined by careHPV was not significantly 
different between BF and SA, prevalence of cytological and histological high-grade lesions 
were markedly higher in SA compared to BF. A similarly high prevalence of lesions among 
HIV-1-infected women in SA has been already reported (Firnhaber et al, 2013) and factors 
that may explain the differences observed between these two countries will be further 
investigated. At least in the HARP study, we can rule out issues of histological 
misclassification as final histological diagnosis of CIN2+ lesions was established by a 
consensus Expert Committee reviewing slides from both countries simultaneously.   
In conclusion, our results indicate that the careHPV test would be a reliable tool for cervical 
cancer screening in WLHA. Such a cost-affordable test should be considered for 
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implementation in cervical cancer prevention programs in sub-Saharan Africa targeting 
women living with HIV/AIDS. 
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Legend Figure 1:  
Study flowchart. BF, Burkina Faso; SA, South Africa. 
 

INNO-LiPA
HPV types No. No. %
HPV 16 41 19 46.3
HPV 18 33 16 48.5
HPV 31 49 22 44.9
HPV 33 16 10 62.5
HPV 35 36 24 66.7
HPV 39 21 9 42.9
HPV 45 20 16 80.0
HPV 51 23 12 52.2
HPV 52 83 43 51.8
HPV 56 25 10 40.0
HPV 58 22 19 86.4
HPV 59 3 2 66.7
HPV66 27 15 55.6
HPV 68 23 10 43.5
Overall 736 408 55.4
Table 1. Detection rate of the 14 high-risk HPV types by the 
care HPV test among samples with single-type HPV infection as 
identified by the INNO-LiPA HPV genotyping Extra assay
care HPV
Cytology No. care HPV-positive (%)
INNO-LiPA-
positive (%) No.
care HPV-positive 
(%)
INNO-LiPA-
positive (%)
No anomalies 368 148 (40.2) 240 (65.2) 14 4 (28.6) 6 (42.9)
Atypical cellsa 16 9 (56.2) 12 (75.0) 84 28 (33.3) 58 (69.0)
LSIL 33 25 (75.8) 28 (84.8) 316 114 (36.1) 215 (68.0)
HSIL+ 9 9 (100) 9 (100) 89 78 (87.6) 81 (91.0)
P b <0.0001 0.0016 <0.0001 0.0011
Table 2. Prevalence of HR-HPV detection by care HPV and INNO-LiPA genotyping Extra assay according to 
cytological results 
Burkina Faso (n=426) South Africa (n=503)
a Atypical squamous cells of undetermined significance (ASC-US), n=13 (BF) and n=52 (SA); Atypical squamous cells, cannot 
exclude HSIL (ASC-H), n=2 (BF) and n=32 (SA); Atypical glandular cells (AGC), n=1 (BF)
b Test for trend
care HPV INNO-LiPA care HPV INNO-LiPA care HPV INNO-LiPA
No. of positive 
tests
206 300 222 358 428 658
No. of CIN2+ 
positive by test 9 8 47 50 56 58
Sensitivity % 100 (66.4-100) 88.9 (51.7-99.7) 92.2 (81.1-97.8) 98.0 (89.6-99.6) 93.3 (83.8-98.2) 96.7 (88.5-99.6)
Specificity % 54.7 (49.9-59.5) 32.9 (28.5-37.5) 60.9 (56.3-65.5) 31.3 (27.0-35.8) 57.9 (54.5-61.2) 32.0 (29.0-35.2)
PPV % 4.4 (2.0-8.1) 2.7 (1.2-5.2) 21.2 (16.0-27.1) 14.0 (10.6-18.0) -a -
NPV % 100 (98.5-100) 99.3 (96.2-100) 98.6 (96.3-99.6) 99.3 (96.1-100) - -
a PPV (positive predictive value) and NPV (negative predictive value) have not been combined for the two countries as they 
depend on disease prevalence/incidence which are different for each country.
Table 3. Performance of the care HPV and INNO-LiPA assays for the diagnosis of CIN2+ lesions (n=943)
Burkina Faso
(CIN2+, n=9)
South Africa
(CIN2+, n=51)
Overall
(CIN2+, n=60)
Performance indicators
Burkina Faso
n (%) care HPV+
South Africa
n (%) care HPV+
CIN2+ 
n Sensitivity % (95%CI)
P value 
(Fisher's 
Exact)
Specificity % 
(95%CI)
P value (chi-
squared for 
trend/chi-
squared)
     <200
     201-350
     >350
35 (64.1)
49 (48.5)
145 (43.0)
23 (50.0)
62 (47.7)
158 (41.5)
10
12
37
80.0 (44.4-97.5)
100.0 (73.5-100)a
94.6 (81.8-99.3)
0.2
45.7 (34.6-57.1)
55.9 (48.6-63.0)
60.2 (56.1-64.1)
0.01 (for trend)
     <200
     201-350
     >350
20 (69.0)
40 (69.0)
157 (41.0)
14 (41.2)
68 (56.7)
159 (40.2)
6
15
38
100.0 (0.54-100)a
93.3 (68.1-99.8)
92.1 (78.6-98.3)
>0.9
50.9 (36.8-64.9)
42.6 (34.4-51.0)
61.8 (57.9-65.5)
0.0008 (for trend)
     <35
     ≥35    
100 (50.3)
129 (44.0)
140 (48.8)
105 (38.5)
36
24
91.7 (77.5-98.2)
95.8 (78.9-99.9) 0.6
54.8 (49.8-59.8)
60.3 (55.8-64.6) 0.1
On ART before enrolment 156 (43.9) 147 (40.7) 38 89.5 (75.2-97.1) 60.6 (56.5-64.5)
ART initiated after enrolment 24 (53.3) 17 (48.6) 3 100 (29.2-100)a 0.4 49.3 (37.2-61.4) 0.05
Not on ART 49 (53.3) 81 (49.4) 19 100 (82.4-100)a 52.9 (45.9-59.9)
a one-sided 97.5% CI
Table 4. Effect of baseline or contemporary CD4 count,  age and antiretroviral therapy (ART) on the performance of care HPV
Baseline CD4 count, cells/mm3
Contemporary CD4 count, cells/mm3
Age, years
ART status
